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Abstract
Purpose—Oncogenic activation of Ras renders cancer cells resistant to ionizing radiation (IR),
but the mechanisms have not been fully characterized. The Ras-like small GTPases, RalA and
RalB, are downstream effectors of Ras function and are critical for both tumor growth and
survival. The Ral effector RalBP1/RLIP76 mediates survival of mice after whole body irradiation
but the role of the Ral GTPases themselves in response to IR is unknown. We have investigated
the role of RalA and RalB in cellular responses to IR.
Methods and Materials—RalA, RalB and their major effectors RalBP1 and Sec5 were
knocked down by stable expression of shRNAs in the K-Ras-dependent pancreatic cancer-derived
cell line MIA PaCa-2. Radiation responses were measured by standard clonogenic survival assays
for reproductive survival, γH2AX expression for double-strand DNA breaks (DSBs) and PARP
cleavage for apoptosis.
Results—Knockdown of K-Ras, RalA or RalB reduced colony-forming ability post-IR and
knockdown of either Ral isoform decreased the rate of DSB repair post-IR. However, knockdown
of RalB, but not RalA, increased cell death. Surprisingly, neither RalBP1 nor Sec5 suppression
affected colony formation post-IR.
Conclusions—Both RalA and RalB contribute to K-Ras-dependent IR resistance of MIA
PaCa-2 cells. Sensitization due to suppressed Ral expression is likely due in part to decreased
efficiency of DNA repair (RalA and RalB) and increased susceptibility to apoptosis (RalB). Ral-
mediated radioresistance does not depend on either RalBP1 or the exocyst complex, the two best-
characterized Ral effectors, and instead may utilize an atypical or novel effector.
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Introduction
Sensitivity of cancer cells to ionizing radiation (IR) is a critical factor in determining the
efficacy of radiation therapy for cancer treatment (1). Intrinsic resistance to IR in some
tumor types, such as pancreatic ductal adenocarcinoma (PDAC), contributes to treatment
challenges (2). K-Ras activity is important in determining the response of many cancer cells
to IR (3-8), particularly in PDAC, nearly all of which have oncogenically activating K-Ras
mutations (2,9). Therefore, understanding the molecular mechanisms by which K-Ras
influences radiation sensitivity or resistance may ultimately improve therapeutic outcomes.
The roles of the two best-characterized Ras effectors, Raf serine/threonine kinases and
phosphatidylinositol 3-kinases (PI3K) in radiation sensitivity have been analyzed in multiple
cell types. In model epithelial cells, PI3K and Raf are both required for maximal H-Ras-
induced radioresistance, although inhibition of these two molecules does not fully
recapitulate inhibition (10,11). Inhibitor studies in pancreatic and colorectal tumor-derived
cell lines indicate that K-Ras can also cause radiation resistance via activation of epidermal
growth factor (EGF) signaling, leading to H-Ras activation and signaling via PI3K (12,13).
Ras binds and activates Ral-specific guanine nucleotide exchange factors (RalGEFs), which
activate RalA and RalB (14-16). RalA and RalB are activated in PDAC cell lines and
tumors, where they serve as critical regulators of proliferation and survival (17). Although
RalA and RalB are 82% identical, and can interact with the same set of downstream
effectors, they have distinct roles in cancer progression. While RalA is critical for
anchorage-independent growth in vitro and tumorigenic growth in mice, RalB is essential
for tumor cell invasion in vitro and metastasis in mice (18-21). Activation of RalA and RalB
is sufficient for Ras-induced transformation of some human cell lines (22).
Ral proteins mediate their activities through multiple downstream effectors. Most notable
are RalBP1/RLIP76, Exo84 and Sec5 (17). RalBP1 is a multifunctional protein that can
function as a GAP for Rho family small GTPases (23). Interestingly, RalBP1 knockdown
causes radiation sensitivity in mice following whole body irradiation (24). Exo84 and Sec5
are subunits of the exocyst, a multiprotein complex that directs certain secretory vesicles to
specific plasma membrane areas (25). Although the mechanisms are unclear, Ral proteins
appear to utilize the exocyst to regulate cell polarity and motility (26,27), properties that are
important to the transformed phenotype.
The importance of Ral proteins and their effectors for oncogenic growth has been revealed
in the last ten years. To date, analysis of the role of Ras effectors in radiation responses has
focused on the best studied effectors, Raf and PI3K. Our goal here was to determine if RalA
or RalB also regulate cellular responses to IR.
Methods and Materials
Expression Plasmids
pSuperRetro shRNA expression constructs (puromycinr) targeting RalA, RalB or a scramble
control (Scr) were described previously (20). We used standard methods to generate (1)
additional shRNA constructs (targeting K-Ras, RalA, RalB, Sec5 or GFP) in pSuperRetro
(puromycinr or blasticidinr) and (2) constructs encoding shRNA-resistant variants of RalA
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or RalB in pBabe (puromycinr). Clones for RalBP1 knockdown were purchased from Open
Biosystems (RHS3979-9615119 and RHS3979-9615121).
Cell Culture and Generation of Cell Lines
MIA PaCa-2 and HEK293T cells were maintained in RPMI-1640 or DMEM-H (Invitrogen),
respectively, supplemented with 5% fetal bovine serum (FBS; Sigma) and antibiotics at
37°C and 5% CO2. To generate stable knockdowns, retroviruses or lentiviruses were
packaged in HEK293T cells. Cells were transfected with retroviral constructs and pVPack
packaging vectors according to the manufacturer's instructions (Stratagene, La Jolla, CA), or
with lentiviral constructs (Open Biosystems) and psPAX2 and pMD2.G packaging vectors
(Addgene) according to the Addgene pLKO.1 protocol. Viruses were harvested and target
cells infected according to above protocols.
Antibodies/Western Blots
Western blots were performed using standard protocols with mouse monoclonal antibodies
as follows: RalA (BD Transduction Laboratories), RalB (Upstate), K-Ras (Calbiochem,
OP24), β-actin (Sigma), γH2AX (Millipore), PARP (BD Pharmingen), RalBP1 (Abnova).
Rabbit anti-Sec5 (28) was used at 1:2000. Secondary antibodies were HRP-conjugated
sheep anti-mouse antibodies or donkey anti-rabbit (Amersham-Pharmacia). All antibodies
were diluted according to manufacturers’ recommendations using 1% bovine serum albumin
in TBS-Tween 20. Antibodies were detected with Supersignal West Dura HRP
chemiluminescent substrate (Pierce Biotechnology).
Clonogenic Survival Assays
MIA PaCa-2 cells stably expressing shRNAs were plated at low density. Approximately 18
h after plating, cells were irradiated with a single dose (2 Gy or 7 Gy) from a Cs137
irradiator (JL Shepherd) at a rate of 150 cGy/min. After two weeks, cells were fixed in
methanol:acetic acid (3:1 v:v) and stained with 1% crystal violet. Colonies were counted
manually using a threshold of 50 cells as a minimum for a viable colony. Plating efficiency
and surviving fraction were calculated as described previously (10).
Results
To assess the role of Ral GTPases in the response of PDAC cells to IR, we utilized MIA
PaCa-2 cells, which exhibit K-Ras-dependent radioresistance, hyper-activation of Ral
proteins, Ral dependent tumorigenic and metastatic growth (9,19,20). We created cell lines
with stable knockdown of RalA or RalB, utilizing previously published constructs to express
shRNAs targeting each Ral protein (20). Constructs encoding shRNAs targeting K-Ras or a
nonspecific (NS) sequence were used as positive and negative controls for
radiosensitization, respectively. As expected, RalA-, RalB-, and K-Ras-targeting shRNAs
produced specific knockdown of target protein expression (Figure 1A). We also observed
that RalA expression was increased in RalB knockdown cells relative to control cells. This
upregulation was reproducible and may represent a compensatory mechanism to deal with
loss of RalB. Why a similar compensatory increase of RalB does not occur in RalA
knockdown cells is unclear.
Post-IR survival was analyzed using standard clonogenic survival assays. Briefly, cells were
plated, irradiated (Mock, 2 Gy or 7 Gy) and allowed to grow for two weeks. Colonies were
counted and surviving fractions (SF) calculated (Figure 1B; see Methods for details). As
expected, K-Ras knockdown resulted in fewer colonies than NS control (SF2: 47.5% versus
78.9%, p<0.01; SF7: 2.6% versus 6.5%, p<0.01), indicating that loss of K-Ras sensitizes
MIA PaCa-2 cells to IR. Knockdown of either RalA or RalB also resulted in significantly
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fewer colonies than NS control at 2 Gy (RalA: SF2=59.5%, p=0.02; RalB: SF2=59.2%,
p=0.01) and 7 Gy (RalA: SF7=4.1%, p=0.02; RalB: SF7=3.8%, p=0.01), indicating that
each Ral isoform contributes to reproductive survival in irradiated MIA PaCa-2 cells. As
expected, K-Ras knockdown caused greater sensitization than knockdown of individual Ral
isoforms, presumably because K-Ras drives additional effector pathways causing
radioresistance (1, 12).
To confirm that radiosensitization was specific to Ral knockdowns, we introduced
uncleavable variants of RalA or RalB into cells expressing each shRNA. Each construct
restored protein expression to normal levels and rescued the clonogenic survival defects
caused by shRNA expression (RalA shRNA SF2=58.4%; RalA shRNA + Rescue SF2=73.7,
p<0.01) (RalA shRNA SF7=2.8%; RalA shRNA + Rescue SF2=7.0, p<0.01) (RalB shRNA
SF2=28.3%; RalB shRNA + Rescue SF2=59.7, p<0.01) (RalB shRNA SF7=2.7%; RalB
shRNA + Rescue SF2=5.3, p<0.01), indicating that the defects are specific to Ral
knockdown (Figure 1C,D).
We also wished to ask if RalA and RalB act redundantly. We generated MIA PaCa-2 cells
that stably expressed shRNAs targeting RalB and either RalA or NS control (Figure 2). We
reasoned that if RalA and RalB act redundantly, RalA/RalB double knockdown cells would
be significantly more sensitive to IR than single knockdowns. In fact, clonogenic survival of
RalA/RalB double knockdown cells was not significantly different from that of RalB
knockdown cells (SF2: NS/RalB=62.4%, RalA/RalB=63.5%, p=0.78; SF7: NS/RalB=4.3%,
RalA/RalB=4.4%, p=0.75). Thus, RalA and RalB are each required for Ral pathway
response to IR in MIA PaCa-2 cells.
We sought to understand the mechanisms whereby Ral knockdowns cause reduced survival
post-IR. Radiation induces reactive oxygen species (ROS) that cause extensive DNA
damage, particularly DSBs. If not repaired properly, DSBs lead to cell death (29). Thus, we
quantified post-IR expression of phospho-H2AX (γH2AX), a marker of DSBs, in Ral
knockdown cell lines (30). MIA PaCa-2 cells stably expressing RalA, RalB, or NS targeting
sequences were exposed to IR, and γH2AX was detected by western blot analysis. Mock IR
was used as a control to define baseline γH2AX expression. As expected, NS control cells
showed a marked increase in γH2AX 1 h post-IR, which declined by 3 h post-IR, indicating
efficient DSB repair (Figure 3). In contrast, MIA PaCa-2 cells with RalA or RalB
knockdown maintained high levels of γH2AX expression 6 h post-IR, suggesting that DSBs
are less efficiently repaired in MIA PaCa-2 cells with Ral knockdowns.
When faced with irreparable damage, cells can undergo apoptosis to prevent proliferation.
RalB is believed to contribute to tumor survival by inhibiting apoptosis (18). Therefore, we
asked whether Ral knockdown altered caspase-dependent apoptosis, as measured by
cleavage of PARP. Cell lysates were collected 24, 48 and 72 h post-IR (7 Gy) and PARP
cleavage was assayed by western blot. As expected, NS control cells displayed elevated
levels of cleaved PARP at 48 and 72 h post-IR. RalA knockdown did not significantly alter
PARP cleavage, while RalB knockdown increased PARP cleavage by 24 h post-IR (earlier
than control cells) and had higher levels of cleaved PARP relative to uncleaved (Figure 4).
These results indicate that RalB, but not RalA, contributes to an anti-apoptotic survival
function.
We next wished to determine which Ral effectors contribute to the Ral-dependent response
to IR. We first analyzed RalBP1 (also known as RLIP76), a multi-domain protein required
for protection against IR in C57BL/6 mice (24). MIA PaCa-2 cells expressing either of two
distinct RalBP1-targeting shRNAs or a NS shRNA control were generated. Analysis of
RalBP1 expression showed each shRNA caused greater than 95% knockdown relative to NS
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control (Figure 5A). Contrary to previous mouse data, RalBP1 knockdown did not sensitize
MIA PaCa-2 cells to IR (Figure 5B; SF2: NS shRNA=70.3%, RalBP1 shRNA#1=74.8%,
RalBP1 shRNA#2=73.0%; SF7: NS shRNA=6.0%, RalBP1 shRNA#1=5.8%, RalBP1
shRNA#2=6.3%).
We next analyzed the role of Sec5, the other major Ral effector. Sec5 is a member of the
exocyst complex that is critically involved in vesicle targeting and can also function
downstream of RalB in cell survival, as RalB activation promotes Sec5 interaction with
TBK1 kinase (31). We generated MIA-PaCa-2 cells stably expressing shRNAs targeting
Sec5 and confirmed knockdown by western blot (Figure 6A). Sec5 knockdown did not
sensitize MIA PaCa-2 cells to IR, suggesting that Ral-mediated post-IR survival does not act
through Sec5 (Figure 6B; SF2: NS shRNA=71.8%, Sec5 shRNA#1=70.8 %, Sec5
shRNA#2=68.7%; SF7: NS shRNA=7.7%, Sec5 shRNA#1=6.4 %, RalBP1
shRNA#2=7.5%).
Discussion
Oncogenic Ras induces IR resistance in many tumor types, including pancreatic cancer,
where over 90% of tumors carry oncogenic mutations in K-Ras. Recent work indicates that
K-Ras-mediated resistance to IR in pancreatic cancer cells is in part dependent upon the Ras
effector PI3K (9), but does not require Raf (1). However, the role of the Ral small GTPases,
which are also important Ras effectors, is unknown. As such, we focused our studies on Ral.
We found that knockdown of either RalA or RalB sensitized MIA PaCa-2 cells to IR.
Although RalA and RalB are 82% identical, they have distinct functions in pancreatic cancer
cells (20). Thus, it was perhaps unexpected that both RalA and RalB sensitized cells to IR.
However, it appears that RalA and RalB do not function via completely overlapping
mechanisms, as knockdown of both proteins simultaneously did not further increase
sensitization.
The molecular mechanisms of Ras-regulated IR response are poorly understood. Ras-
induced resistance has been proposed to function through modulation of cell cycle
checkpoints, as oncogenic H-Ras causes resistance and prolongation of G2 phase in primary
rat embryo cells (32-34). Additionally, oncogenic H-Ras expression enhances repair of
gamma-, UV- and cisplatin-induced DNA damage in NIH 3T3 cells (35,36). The ability to
repair DSBs is widely considered the most critical factor controlling IR sensitivity (37). As
such, we used γH2AX as a marker of IR-induced DSBs. As expected, γH2AX expression
increased shortly after IR regardless of Ral expression levels. In control cells, γH2AX levels
declined by 3 h after IR while RalA and RalB knockdown resulted in high γH2AX levels for
at least 6 h. RalB knockdown resulted in a slightly weaker defect than did RalA knockdown.
RalA upregulation in RalB knockdown cells may explain this difference. It would also be
interesting to determine whether there are differential Ral isoform effects on S-phase
distribution following radiation, which could further impact total cellular γH2AX. To our
knowledge, this is the first study to show a role for Ral proteins in repair of IR-induced
DNA damage. Interestingly, in immortalized fibroblasts and an osteosarcoma-derived p53-
deficient cell line, oncogenic H-Ras also inhibits the G2-M checkpoint in a manner
dependent on Ral proteins but not RalBP1 (38,39). This is consistent with our findings that
RalBP1 does not mediate Ral-dependent changes in IR responses in MIA PaCa-2 cells,
which are also p53-deficient. Ral proteins also drive activation of cyclin D1 and cell cycle
progression from G1-S in a RalBP1-independent manner (40). Thus, Ral proteins are
involved in two distinct cell cycle checkpoints. It will be of interest in future studies to
determine if modulation of these checkpoints is utilized by Ral to render cells radioresistant.
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Given previous reports indicating that RalB functions as an anti-apoptotic factor, we
analyzed PARP cleavage to measure caspase-3-dependent apoptosis (18,20). We found that
control and RalA knockdown cells exhibited similar PARP cleavage kinetics post-IR. Since
RalA knockdown decreases clonogenic survival and perturbs DSB resolution, we conclude
that RalA likely contributes to cell death primarily via a caspase-independent mechanism,
such as post-mitotic catastrophe (41). In constrast to control and RalA knockdown, RalB
knockdown caused more rapid induction of apoptosis. This is consistent with published data
indicating that RalB normally inhibits apoptosis (18). RalB engages Sec5, which in turn
binds and activates TBK1 kinase to promote survival (31,42). As Sec5 knockdown did not
cause IR sensitivity, it is possible that RalB-dependent apoptosis is not a major contributor
to IR sensitivity of MIA PaCa-2 cells. Alternatively, RalB-dependent apoptosis may occur
via a Sec5-independent mechanism and constitute a significant component of IR sensitivity.
RalBP1 is a multi-domain protein with diverse functions (17,43,44). It can protect cells by
transporting toxic metabolites (45). RalBP1 is critical for IR response in mice and mouse
embryonic fibroblasts (24,46). Thus, RalBP1 was an excellent candidate for mediation of
Ral-dependent IR resistance, and we were surprised that RalBP1 knockdown had no
significant effect on clonogenic growth of MIA PaCa-2 cells post-IR. It is unlikely that
knockdown was insufficient to reduce clonogenic survival in this context, since RalBP1
protein was reduced by ~90%. Instead, our findings likely differ from previous reports on
RalPB1 due to differences in cell type or cell context. In future analyses, it will be
interesting to see whether tumor type- or cell type-specific genetic alterations can predict a
requirement for Ral in radiation responsiveness.
We next considered a Ral effector that is part of the exocyst, a protein complex involved in
vesicle targeting. The exocyst is important for processes including establishing and
maintaining cell polarity. It has been suggested that exocyst-induced polarity changes alter
cell proliferation and survival (25). Ral directly regulates exocyst formation via interaction
with two components, Sec5 and Exo84 (47). We thought it plausible that Ral proteins direct
specific exocyst-mediated protein and membrane movements that control IR response.
However, our clonogenic survival assays indicated that Sec5 knockdown does not alter IR
response of MIA PaCa-2 cells.
Other Ral effectors have been identified, although their roles in oncogenesis remain poorly
characterized. Although not a classical Ral effector pathway, in that interaction does not
depend on GTP binding, Ral activation of phospholipase D1 (PLD1) has been implicated in
cytokinesis and other cellular processes (48,49). Ral proteins also transmit signals using
ZONAB, a Y-box transcription factor that is regulated by association with Ral. ZONAB is
unlikely to mediate Ral-dependent changes in IR sensitivity because the interaction between
RalA and ZONAB occurs only when cells are grown at high density (50), whereas RalA and
RalB knockdowns significantly alter IR response of cells grown in isolation.
In conclusion, our results indicate that both RalA and RalB make significant contribution to
K-Ras dependent IR resistance of MIA PaCa-2 pancreatic cancer cells. Sensitization due to
knockdown of RalA or RalB is, at least in part, due to decreased ability to repair DNA
damage. RalB knockdown also may cause sensitization by increasing susceptibility to
apoptosis. Neither canonical effector, RalBP1 nor Sec5, has a significant individual role in
post-IR survival. Thus, it will be interesting to determine whether irradiation causes Ral
proteins to engage atypical or novel effectors.
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Figure 1. Knockdown of either RalA or RalB sensitizes MIA PaCa-2 pancreatic cancer cells to
ionizing radiation (IR)
MIA PaCa-2 cells stably expressing shRNAs targeting RalA, RalB, K-Ras, or a non-specific
sequence (NS) were generated. (a) Lysates were analyzed by immunoblotting (IB) to
determine expression of RalA, RalB and K-Ras. β-actin was a loading control. Knockdowns
of RalA, RalB and K-Ras were robust and specific. (b) Knockdown cells were analyzed by
standard clonogenic growth assay following treatment with the indicated doses of IR. As
expected, knockdown of K-Ras sensitized cells to IR. C Knockdown of either RalA or RalB
also resulted in decreased survival post-IR. (c, d) shRNA-resistant (“rescue”) versions of
either RalA or RalB were stably expressed in cells expressing RalA or RalB shRNAs,
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respectively. (c) Top, RalA protein re-expression was confirmed by IB; bottom, RalA re-
expression rescued clonogenic growth defects associated with RalA shRNA expression. (d)
Top, RalB protein re-expression was confirmed by IB; bottom, RalB re-expression rescued
clonogenic growth defects associated with RalB shRNA expression. All results shown are
representative of at least three independent experiments. Clonogenic survival assays were
performed at least three times in triplicate. Bars represent mean ± standard deviation.
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Figure 2. RalA/B double knockdowns do not further sensitize MIA PaCa-2 cells to IR
MIA PaCa-2 cells simultaneously and stably expressing shRNAs targeting RalA and RalB
or NS and RalB were generated. Top, cells were analyzed by IB to confirm knockdown.
Bottom, clonogenic growth assay indicates that knockdown of both Ral proteins did not
result in an additional decrease in post-IR survival compared to knockdown of either protein
alone. Clonogenic survival assays were performed at least three times in triplicate. Bars
represent mean ± standard deviation.
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Figure 3. Loss of either RalA or RalB increases persistence of the DSB marker γH2AX
γH2AX expression was used as a marker of DSB. Top panels, Immunoblot analysis of
γH2AX levels at indicated times after administration of IR (7 Gy). Bottom panels,
immunoblot analysis of the loading control, β-actin. Relative γH2AX expression was
quantified by densitometry of immunoblots and normalized to β-actin. In cells in which
RalA or RalB expression had been knocked down, γH2AX expression remained elevated at
time points after it was restored to background levels in control (NS) cells.
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Figure 4. Loss of RalB but not RalA sensitizes MIA PaCa-2 cells to IR-induced apoptosis
Poly (ADP-ribose) polymerase (PARP) cleavage was used to determine if IR-induced
apoptotic cell death is altered by RalA or RalB knockdown. Cells were irradiated with 7 Gy
and lysates were collected at the indicated time points (in hours) or after mock irradiation
(M). Top panels show immunoblots probing for PARP. Cleaved PARP is marked by a grey
arrowhead. Bottom panels show immunoblots of β-actin loading control. In control (NS) and
RalA knockdown cells, PARP cleavage at 24 h was similar to mock (M), with most PARP
cleaved by 48 h. By contrast, in RalB knockdown cells a majority of PARP was cleaved
after only 24 h.
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Figure 5. Radiosensitivity due to loss of RalA or RalB is not mediated by the canonical Ral
effector RalBP1
(a) Lysates from cells expressing the indicated shRNAs were analyzed by immunoblot (IB)
to confirm RalBP1 knockdown. (b) Cells with each protein knocked down were analyzed by
clonogenic growth assay. Unexpectedly, knockdown of RalBP1 did not alter colony
formation. Clonogenic survival assays were performed at least three times in triplicate. Bars
represent mean ± standard deviation.
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Figure 6. Radiosensitivity due to loss of RalA or RalB is not mediated by the exocyst component
Sec5
(a) Lysates from cells expressing the indicated shRNAs were analyzed by immunoblot (IB)
to confirm Sec5 knockdown. (b) Cells with each protein knocked down were analyzed by
clonogenic growth assay. Knockdown of Sec5 did not alter colony formation. Clonogenic
survival assays were performed at least three times in triplicate. Bars represent mean ±
standard deviation.
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